Loading stock data…
CVRX
$7.97+0.46 (+6.13%)
Market ClosedLast close May 1
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CVRx, Inc. in the Healthcare sector is trading at $7.97. The stock is currently 29% below its 52-week high of $11.30, remaining 0.9% below its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why CVRX maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.97
Potential Upside
5%
Whystock Fair Value$8.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$209.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-135.56%
Volume
Today's trading volume
344,896
Recent News
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CVRx (CVRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ...
CVRx Inc (CVRX) reports increased revenue and expanded sales territories, while navigating financial hurdles and strategic transitions.
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
There's been a major selloff in CVRx, Inc. ( NASDAQ:CVRX ) shares in the week since it released its full-year report...
CVRx, Inc. Q4 2025 Earnings Call Summary
Moby summary of CVRx, Inc.'s Q4 2025 earnings call
CVRx Q4 Earnings Call Highlights
CVRx (NASDAQ:CVRX) reported fourth-quarter revenue of $16.0 million and full-year revenue of $56.7 million, representing growth of 4% and 10%, respectively, as the company continued investing in its commercial organization and initiatives aimed at expanding adoption of its Barostim therapy for heart